الفهرس Only 14 pages are availabe for public view
 |  | from | 198 |  |  |
| | | from | 198 | | |
Abstract
Atherosclerotic disease remains the leading cause of death despite major advances in its diagnosis, treatment, and prevention. The increasing epidemic of obesity, IR, and diabetes will likely add to this burden. Increasingly, it is becoming apparent that adipose tissue is an active endocrine and paracrine organ that releases several bioactive mediators that influence not only body weight homeostasis but also inflammation, coagulation, fibrinolysis, IR, diabetes, and atherosclerosis. Adiponectin, the most abundant circulating adipocytederived protein identified (Laughlin et al., 2006), adiponectin are associated with the prevalence of CAD, which is independent of well-known CAD risk factors. High concentrations of adiponectin are associated with a lower risk of MI, which is also independent of inflammation and glycemic status and can be only partly explained by differences in blood lipids. These clinical studies suggest that the protective effect of adiponectin on the development of CAD may be primary rather than secondary through the protection of metabolic abnormalities, such as IR. This study aims to assess the serum adiponectin level in diabetic and non diabetic patients with (CAD), and its relation to other variable risk factors of CAD.This study was carried out on 88 subjects, who divided into 3 groups: Group A included 34 diabetic patients with coronary artery diseases Group B included 34 non diabetic patients with coronary artery diseases. Group C included 20 healthy persons as a control group. Measurement of obesity indicators, fasting blood glucose, insulin, insulin resistance index, complete lipid profile and serum adiponectin were done.